SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank50
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P50
Within normal range
vs 5Y Ago
-0.4x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025-32.00%
2024-36.79%
20231.21%
2022-186.11%
2021-228.46%
202072.24%
20190.00%